Difference between revisions of "Part:BBa K4156086"
(One intermediate revision by the same user not shown) | |||
Line 3: | Line 3: | ||
<partinfo>BBa_K4156086 short</partinfo> | <partinfo>BBa_K4156086 short</partinfo> | ||
− | + | CCL21 is an anti-tumor protein. | |
+ | |||
+ | <!-- Add more about the biology of this part here --> | ||
− | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
− | < | + | It activates host immune response through recruitment of T cells and dendritic cells.<sup>[1]</sup> CCL21 is used as a therapeutic component to confer therapeutic capability to engineered strains against CRC tumor cells. |
+ | |||
+ | |||
+ | ===References=== | ||
+ | |||
+ | <i> | ||
+ | 1 Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother. May 2009;58(5):769-75. doi:10.1007/s00262-008-0555-9 | ||
+ | |||
+ | </i> | ||
+ | |||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K4156086 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4156086 SequenceAndFeatures</partinfo> |
Latest revision as of 11:51, 11 October 2022
CCL21
CCL21 is an anti-tumor protein.
Usage and Biology
It activates host immune response through recruitment of T cells and dendritic cells.[1] CCL21 is used as a therapeutic component to confer therapeutic capability to engineered strains against CRC tumor cells.
References
1 Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother. May 2009;58(5):769-75. doi:10.1007/s00262-008-0555-9
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]